^
    Back
    Association details:
    Biomarker:MYD88 mutation
    Cancer:Marginal Zone Lymphoma
    Drug:Brukinsa (zanubrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood Adv
    Title:

    Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma

    Published date:
    07/14/2023
    Excerpt:
    MYD88 or TNFAIP3 mutations correlated with improved progression-free survival (PFS). KMT2D mutations trended to worse PFS….All 8 of these patients with tumors harboring mutations of MYD88 or TNFAIP3 achieved an objective response and had prolonged PFS (median PFS, NR vs 11.1 months; P= 0.008...In summary, the correlative studies described herein have demonstrated that mutations in MYD88 and TNFAIP3 associate with improved PFS, and mutations in KMT2D may associate with reduced PFS for patients with rrMZL treated with zanubrutinib.
    DOI:
    10.1182/bloodadvances.2022009412
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2022
    Title:

    ALLG LABORATORY SCIENCE STUDY LS21: MOLECULAR CORRELATES OF RESPONSE IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (RRMZL) PATIENTS TREATED WITH ZANUBRUTINIB IN THE MAGNOLIA TRIAL

    Published date:
    05/12/2022
    Excerpt:
    Patients with either MYD88 or TNFAIP3 mutations had improved median PFS (not reached (NR) vs 11.1 months, p: 0.009, HR: 0.09, 95% CI: 0.02-0.55)…
    Trial ID:
    MAGNOLIA